Nitric oxide "at heart": emerging paradigms after a decade

Area of Science:

• Cardiovascular Physiology
• Molecular Cardiology
• Pharmacology

Background:

• Nitric oxide synthase (NOS) isoforms exhibit functional redundancy in the heart.
• Subcellular localization of NOS isoforms dictates their specific signaling pathways and interactions with effectors.
• Stimuli such as physical stretch and receptor activation modulate NOS activity.

Purpose of the Study:

• To elucidate the distinct roles of eNOS, nNOS, and iNOS in normal and diseased cardiac function.
• To understand how NOS isoforms modulate cardiac contractility, electrophysiology, and autonomic regulation.
• To explore the therapeutic potential of targeting NOS for cardiovascular diseases.

Main Methods:

• Genetic deletion and overexpression studies in cardiac models.
• Analysis of NOS isoform expression and activity in response to physiological and pathological stimuli.
• Investigation of NOS interactions with cardiac receptors and signaling pathways.

Main Results:

• eNOS and nNOS support normal excitation-contraction coupling and the Frank-Starling mechanism.
• NOS isoforms attenuate adrenergic and enhance vagal control of cardiac function.
• iNOS is induced in ischemic and failing hearts, contributing to altered inotropic responses.
• nNOS expression increases in aging and ischemic hearts, with its role still under investigation.
• Many cardiovascular drugs upregulate eNOS, suggesting a protective role as an endogenous beta-blocker.

Conclusions:

• Cardiac NOS isoforms play critical, isoform-specific roles in regulating heart function.
• Targeting NOS offers a promising strategy for developing novel cardiovascular therapies.
• Future research should focus on the precise modulation of cardiac NOS for improved therapeutic outcomes.